2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
107
Carcinoma, Renal Cell
74
Neoplasm Metastasis
48
Neoplasms
37
Neuroendocrine Tumors
35
Kidney Neoplasms
27
Recurrence
19
Tuberous Sclerosis
18
Carcinoma, Non-Small-Cell Lung
17
Prostatic Neoplasms
16
Triple Negative Breast Neoplasms
15
Lymphoma
15
Lymphoma, Mantle-Cell
14
Lymphoma, Large B-Cell, Diffuse
14
Head and Neck Neoplasms
14
Glioblastoma
14
Carcinoma, Hepatocellular
14
Colorectal Neoplasms
13
Stomach Neoplasms
12
Lung Neoplasms
12
Leukemia, Lymphocytic, Chronic, B-Cell
12
Hodgkin Disease
12
Brain Neoplasms
12
Sarcoma
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Pancreatic Neoplasms
11
Glioma
11
Waldenstrom Macroglobulinemia
10
Lymphoma, Follicular
10
Carcinoma, Neuroendocrine
10
Interventions
Acupuncture Therapy
10
Exercise
7
Cryotherapy
6
Paclitaxel
5
Glutamine
5
Surveys and Questionnaires
3
Duloxetine Hydrochloride
3
Dexamethasone
3
Bortezomib
3
Acetylcysteine
3
Thioctic Acid
2
Tablets
2
Sodium Chloride
2
Saline Solution
2
Physical Therapy Modalities
2
Low-Level Light Therapy
2
Lenalidomide
2
Fish Oils
2
Fatty Acids, Omega-3
2
ziconotide
1
sagopilone
1
pembrolizumab
1
nicotinamide-beta-riboside
1
nabilone
1
glutamic acid diethyl ester
1
eribulin
1
enfortumab vedotin
1
allantoicase
1
Yoga
1
XELOX
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Peripheral Nervous System Diseases
×
Everolimus
×
Clear all
NCT01490476
2017-05-23
AFINF2
Assistance Publique - Hôpitaux de Paris
Phase 2
Completed
10 enrolled